Showing 1 - 9 of 9 Polly Niravath
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Alexys Brock

Phone: 346.238.4814

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet know ... Read more >

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Alexys Brock

Phone: 346.238.4814

The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a dru ... Read more >

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Kelsey Banaglorioso

Phone: 346.238.5740

This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic). Drugs used in chemothera ... Read more >

Acupuncture Trial

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Alexys Brock

Phone: 346.238.4814

A single arm pilot study of 20 patients will be used to determine the feasibility of EA as a treatment for cancer survivors who have been treated with curative intent, but who have persistent CIPN for ?3 months after the cancer treatment is comp ... Read more >

Clinical Phase Ib/II Trial of L-NMMA Plus Docetaxel in the Treatment of Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Rabia Hashmani

Phone: 346.238.5894

This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or metastatic triple neg ... Read more >

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Rabia Hashmani

Phone: 346.238.5894

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane. ... Read more >

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator:

Phone:

Primary Objective: • To compare the efficacy of DS-8201a to investigator’s choice by means of progression-free survival (PFS). Secondary Objectives: • To further investigate the efficacy of DS-8201a compared to investigator’s choice on: ? ... Read more >

PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Kelsey Banaglorioso

Phone: 346.238.5740

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). ... Read more >

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

Status: Open Not Enrolling

Investigator: Polly Niravath

Study Coordinator: Alexys Brock

Phone: 346.238.4814

This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens. ... Read more >